- Etripamil significantly decreased heart rate during SVT episodes and independent of conversion to SR – - HR changes occurred within 5 minutes and were sustained for 60 minutes – - Data presented at AHA Scientific Sessions 2021 - MONTREAL and CHARLOTTE, N.C., Nov.

MONTREAL and CHARLOTTE, N.C., Nov. 12, 2021 /PRNewswire/ --  Milestone Pharmaceuticals Inc.  (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the third quarter ended September

MONTREAL and CHARLOTTE, N.C. , Nov. 11, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive

MONTREAL and CHARLOTTE, N.C., Sept. 22, 2021 /PRNewswire/ --  Milestone Pharmaceuticals Inc.  (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Amit Hasija, Chief Financial Officer and Executive

MONTREAL and CHARLOTTE, N.C., Sept. 7, 2021 /PRNewswire/ --  Milestone Pharmaceuticals Inc.  (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive

MONTREAL and CHARLOTTE, N.C., Aug. 11, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc.  (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the second quarter ended June 30,

MONTREAL and CHARLOTTE, N.C., May 26, 2021 /PRNewswire/ --  Milestone Pharmaceuticals Inc.  (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive

- Statistically Significant Improvements in PSVT-Associated Symptoms and Less ER Visits Observed in Patients Treated with Etripamil Compared to Placebo in the NODE-301 Trial - - Data Presented at the American College of Cardiology's 70th Annual Scientific Session - MONTREAL and Charlotte, N.C., May

MONTREAL and CHARLOTTE, N.C., May 17, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc.  (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the first quarter ended March 31,

- Ji Xing Pharmaceuticals to develop and commercialize etripamil for patients with PSVT in Greater China - - Milestone to receive a $15 million upfront cash payment and a $5 million equity investment by RTW Investments, LP - MONTREAL and CHARLOTTE, N.C., May 17, 2021 /PRNewswire/ -- Milestone